Public Profile

GALAPAGOS

GALAPAGOS NV, commonly referred to as Galapagos, is a pioneering biotechnology company headquartered in the United States, with significant operations in Europe. Founded in 1999, Galapagos has established itself in the pharmaceutical industry, focusing on the discovery and development of innovative medicines for various diseases, including inflammatory and fibrotic conditions. The company is renowned for its unique drug discovery platform, which leverages advanced technologies to identify and develop novel therapeutic candidates. Notable achievements include the successful development of several clinical-stage programmes, positioning Galapagos as a leader in the biopharmaceutical sector. With a commitment to scientific excellence and a robust pipeline, Galapagos continues to make significant strides in transforming patient care through groundbreaking therapies.

DitchCarbon Score

How does GALAPAGOS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Education Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

24

Industry Benchmark

GALAPAGOS's score of 25 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.

75%

Let us know if this data was useful to you

GALAPAGOS's reported carbon emissions

GALAPAGOS, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or climate commitments outlined in their initiatives. Without concrete figures or defined goals, it is challenging to assess their carbon footprint or climate strategy. However, the absence of emissions data and reduction targets may indicate a need for enhanced transparency and commitment to climate action within the industry. As climate change continues to be a pressing global issue, it is essential for companies like GALAPAGOS to establish measurable targets and report on their emissions to contribute effectively to sustainability efforts.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. GALAPAGOS's primary industry is Education services (80), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for GALAPAGOS is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

GALAPAGOS is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Pfizer

US
Pharmaceutical Preparation Manufacturing
Updated about 13 hours ago

Abbvie

US
Chemicals nec
Updated 1 day ago

Takeda

JP
Pharmaceutical Preparation Manufacturing
Updated 7 minutes ago

Organon Pharmaceuticals Usa Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Janssen Biotech, Inc.

US
Health and social work services (85)
Updated 4 months ago
DitchCarbon Score

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers